|
Olga Laskina, PhD, discusses visible particles and manufacturing defects of the packaging components as well as the impact these defects can have on container closure integrity and functional characteristics.
|
|
|
Graham Kelly, Founder, Executive Chairman, and CEO of Noxopharm, discusses the company’s innovative approach to cancer treatment.
|
|
|
Kaiser J. Aziz, PhD, provides an in-depth overview of biosimilar products development and the evaluation criteria for FDA approval.
|
|
|
In part 1 of this 4-part series, PharmaCircle, in collaboration with Drug Development & Delivery, focuses on a global review of 2019 product approvals.
|
|
|
|
|

Recipharm is a leading contract development and manufacturing organisation (CDMO) headquartered in Stockholm, Sweden. We operate development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and are continuing to grow and expand our offering for our customers. Employing around 6,000 people, we are focused on supporting pharmaceutical companies with our full-service offering, taking products from early development through to commercial production. For over 20 years we have been there for our clients throughout the entire product lifecycle, providing pharmaceutical expertise and managing complexity, time and time again. Click here for more.

Looking for an experienced and committed steriles CDMO? Look no further than Pii. Pii has a strong pedigree of scientific know-how and regulatory experience across a range of dosage forms, including capacity for aseptic fill-finish. Our commitment to this market and our capabilities have grown further with investment in a new, fully-robotic aseptic filling line. With expanded capacity for small to medium-batch production of commercial and clinical materials, we are eager to discuss your needs, so we can help advance your sterile product. Click here for more.
|